Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Sill

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Leukemia|December 13, 2003
High expression of the sister-chromatid separation regulator and proto-oncogene hSecurin occurs in a subset of myeloid leukaemias but is not implicated in the pathogenesis of aneuploidyH W Auner, A Zebisch, M G Schimek, et al.
European Journal of Haematology|September 25, 2002
Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamideH W Auner, C Tinchon, R I Brezinschek, et al.
Human Molecular Genetics|February 5, 1999
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignanciesP L Dahia, R C Aguiar, J Alberta, et al.
Leukemia|April 16, 2004
RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implicationsH H Schmidt, S Strehl, D Thaler, et al.
Annals of Hematology|June 1, 1996
Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study GroupJ Thaler, G Gastl, T Fluckinger, et al.
Diabetes & Metabolism|March 11, 2017
Hyperglycaemia within the first month after allogeneic haematopoietic stem-cell transplantation is an independent risk factor for overall survival in patients with acute myeloid leukaemiaF Aberer, S Kremser, J K Mader, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trialM A Fridrik, H Hausmaninger, W Linkesch, et al.
Leukemia|March 6, 2012
Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemiaA Zebisch, A Wölfler, I Fried, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 15, 2001
BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemiaS M Tanner, J L Austin, G Leone, et al.
Leukemia Research|January 1, 1997
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II studyJ Thaler, W Hilbe, U Apfelbeck, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Leukemia|December 13, 2003
High expression of the sister-chromatid separation regulator and proto-oncogene hSecurin occurs in a subset of myeloid leukaemias but is not implicated in the pathogenesis of aneuploidyH W Auner, A Zebisch, M G Schimek, et al.
European Journal of Haematology|September 25, 2002
Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamideH W Auner, C Tinchon, R I Brezinschek, et al.
Human Molecular Genetics|February 5, 1999
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignanciesP L Dahia, R C Aguiar, J Alberta, et al.
Leukemia|April 16, 2004
RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implicationsH H Schmidt, S Strehl, D Thaler, et al.
Annals of Hematology|June 1, 1996
Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study GroupJ Thaler, G Gastl, T Fluckinger, et al.
Diabetes & Metabolism|March 11, 2017
Hyperglycaemia within the first month after allogeneic haematopoietic stem-cell transplantation is an independent risk factor for overall survival in patients with acute myeloid leukaemiaF Aberer, S Kremser, J K Mader, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trialM A Fridrik, H Hausmaninger, W Linkesch, et al.
Leukemia|March 6, 2012
Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemiaA Zebisch, A Wölfler, I Fried, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 15, 2001
BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemiaS M Tanner, J L Austin, G Leone, et al.
Leukemia Research|January 1, 1997
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II studyJ Thaler, W Hilbe, U Apfelbeck, et al.
Pageof 8